TWIST-1 gene's role in hair loss and potential as a treatment target. Inhibiting TWIST-1 may prolong hair growth and reduce hair follicle sensitivity to DHT.
Tretinoin and microneedling both enhance hair growth through different mechanisms, with microneedling being considered safe for long-term use. Optimal microneedling needle length varies, but 0.8 mm is suggested for hair growth, and a Dermastamp is recommended to avoid skin damage.
A female user has experienced severe hair shedding since stopping birth control in late 2022, diagnosed as telogen effluvium with no signs of androgenetic alopecia. Despite healthy living and optimal bloodwork, she continues to shed hair daily but also sees significant regrowth.
The conversation is about a user preparing to join the ABS-201 clinical trial for hair loss treatment, which involves a prolactin inhibitor. The user plans to update others on their progress if enrolled.
Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.
Pyrilutamide Phase 3 approved, starting early 2022 with 416 subjects for 24 weeks. Drug potentially better than RU and Breezula, with some users reporting no side effects.
The user is seeking help with using Ell-Cranell for hair loss treatment. They are unsure about the correct application method and dosage. They also inquire about combining microneedling with topical alfatradiol and question a study that referred to alfatradiol as a hair growth inhibitor in male mice.
The user has been using oral minoxidil (3mg) and finasteride (1.2mg) for 3 months. Some users notice hair growth, especially at the temples and crown, while others see no difference.
PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.
A user is considering mixing Stemoxydine, RU-58841, Alfatradiol, and Tretinoin into a single topical solution for hair loss. They are concerned about potential interactions that could reduce the effectiveness of these ingredients.
A user is considering an extensive hair loss treatment regimen including oral dutasteride, oral minoxidil, topical finasteride, tretinoin, microneedling, keto shampoo, laser comb, and PRP injections. Suggestions include simplifying the routine, possibly increasing minoxidil dosage, and considering alternatives like RU58841, while cautioning against using estrogen due to potential side effects.
TDM-105795 showed better efficacy and safety in trials for hair loss, with a higher hair count improvement compared to GT20029 and HMI 115, but it's not as widely discussed. The user is questioning why this is the case.
The user is three months into using topical finasteride, minoxidil, and tretinoin for hair loss, noticing slight improvement in hair density. They plan to continue treatment and expect more visible results between 6 to 9 months, with the goal of stabilizing hair loss and possibly achieving some regrowth.
The conversation discusses skepticism about the effectiveness of scalp tension theory and scalp massagers for hair regrowth, contrasting it with treatments like finasteride and minoxidil, which have more user-reported results. Participants question the belief in scalp tension theory, suggesting it may be a marketing tactic, while others argue for a multifactorial approach to hair loss.
Hair regrowth after 13 weeks using topical minoxidil, oral finasteride, peptide shampoo, serum, and a red light hat. Some growth is attributed to a recent hair transplant.
PP405, a topical LDH inhibitor, has shown to stimulate hair follicle stem cell proliferation in humans with moderate hair loss. They are advancing to more detailed trials this year.
Estrogen injections significantly improved hair growth, particularly on the crown, after stopping finasteride. Monotherapy with estrogen led to hairline improvement, but also caused sterility and potential feminization effects.
The user experienced hair thinning from chromium and alpha lipoic acid supplements, which stopped after discontinuing them. Someone mentioned this could be telogen effluvium, a temporary condition.
The conversation is about frustration over the delay in phase 2 results for a hair loss treatment called GT20029. One user suspects the treatment may have failed.
The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, and RU58841. It also references Epibiotech's hair multiplication and cell therapy as potential solutions.
A user's experience with microneedling monotherapy and potential treatments such as finasteride, minoxidil, Stemoxydine, rosemary oil, peppermint oil, and RU58841 for reversing hair loss.
The user is happy with hair regrowth after using finasteride, minoxidil, and microneedling for three months. Others comment on the progress and ask about the routine, lighting, and potential side effects.
A user's progress after 15 months of using the "Big 3" treatments for hair loss (finasteride, minoxidil and micro needling) as well as Nizerol 2%. The post encourages others to seek out available information on hair loss treatment and reassures them that if it doesn't work, it is only hair.
Treating hair loss with various remedies, such as Cetirizine and the Big3 complex (minoxidil, finasteride, and RU58841), which have properties like adipogenic, anti-fibrotic and anti-inflammatory. References to research studies are also included.
User shared progress pictures showing increased hair density after 3 months using 5% Minoxidil, Keto shampoo, and supplements. They recently started finasteride for AGA and plan to update in 3 months.
A phase 3 trial for Breezula (clascoterone solution) to treat male pattern hair loss has been listed, with 726 participants and a completion date of January 2025. Other treatments mentioned include Aneira Pharma's combination of minoxidil and latanoprost, Triple Hair's combination of minoxidil, latanoprost, and finasteride, and a new microneedling and LLLT device called StimuSIL.
The conversation discusses hair loss treatments, specifically using Minoxidil, finasteride, and RU58841. It also mentions the importance of raising vitamin D3 levels.
The user is using a hair loss regimen involving 2ddr applied twice daily, tretinoin weekly, and occasionally micro-needling. They report feeling increased scalp thickness and seeing some hair growth progress.
The conversation is about optimism for new hair loss treatments like Stemson's bioengineering, osteopotin, SCUBE3, GT20029, and Verteprofin, and inquires about other notable treatments.